AstraZeneca's Farxiga fails to meet primary goal as potential Covid-19 treatment

Writer,

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Pharmaceutical maker AstraZeneca and Saint Luke's Mid America Heart Institute said high-level results from the a phase 3 trial assessing the potential of Farxiga (dapagliflozin) to treat patients hospitalised with COVID-19 failed to meet its primary goal.

The trial didn't achieve statistical significance for the primary endpoint of 'prevention measuring organ dysfunction and all-cause mortality, and the primary endpoint of recovery measuring a change in clinical status (from early recovery to death), at 30 days,' the company said.

The full trial results would be presented at the American College of Cardiology Scientific Sessions in May 2021.